Verdiva Bio (alt)
Last verified 2026-04-30. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $411.0Mattributed |
|---|---|
| Latest round | series-a, $411.0M, 2025-01-01attributed |
| Founded | unknown |
| Headquarters | London |
| Industry | bio |
| Stage | series-a |
| Website | verdiviabio.com |
Verdiva Bio is a UK clinical-stage biotech advancing oral GLP-1 and incretin-based therapies for obesity and cardiometabolic disease. Patients with obesity are the eventual target population. The lead program VRB-101 is in Phase 2 trials as a once-weekly oral peptide.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | series-a | $411.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $411.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $411.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | verdiviabio.com, read 2026-04-30 |
| Description | self-reported | verdiviabio.com, read 2026-04-30 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.